Deep Track Capital and RTW Investments, two private equity firms. led a $149m Series B round in Apogee Therapeutics, a biotechnology company, with participation from Fidelity Management & Research Company, OrbiMed, Perceptive Advisors, RA Capital Management, Wellington Management, Fairmount and Venrock Healthcare Capital Partners. "Apogee is advancing a pipeline of potential best-in-class therapies targeting clinically validated biological pathways with the potential to drastically impact the lives of millions living with immunological and inflammatory disorders. We appreciate the confidence that our investor syndicate, including founding investors Fairmount and Venrock, has demonstrated in our team and strategy to emerge as a leader in serving this significant patient population," Michael Henderson, Apogee CEO.